• CG had a rare genetic mitochondrial illness and the parents had found a US team at a reputable medical centre who were trialling new treatment, the efficacy of which was unknown.

    As first instance, the Court followed a traditional best interest analysis whereby a balance sheet of factors weighing risks and benefits is drawn up. The Court looks at the child’s welfare in the widest sense, not just clinical and a declaration was made that treatment other than palliative care was not in CG’s best interests.

    The parents challenged that decision and it was argued that parents are in a privileged position to give or withhold consent which can only be overridden if their chosen option was likely to cause the child significant harm.

    The Court of Appeal held that test did not apply in medical treatment cases. It is often a difficult balance, especially where there is nothing to choose between the benefits and detriments of different treatment options. The Court of Appeal concluded that even if the significant harm test had to be applied the experimental US treatment could not be said to provide any significant benefit and the Court resorted to the traditional principles of what was in CG’s best interest balancing the various risks and benefits based on expert evidence.

    This content is correct at time of publication

    Can we help?

    Take a look at our Healthcare page for useful information, resources, guidance, details of our team and how we may be able to help you

  • Get in touch

    Please fill out the below form or alternatively you can call us on 01622 690691

      By submitting an enquiry through 'get in touch' your data will only be used to contact you regarding your enquiry. If you subscribe to any of our newsletters, you can unsubscribe any time using the link in the email. Please view our privacy statement for more information